Table 2 Clinical and laboratory data from SCLC patients stratified by NLR

Age (years, ± SD)

57.61 ± 10.63

107

60.81 ± 9.70

32

Gender (male/female)

81/26

107

26/6

32

Stage (LD/ED)

50/57

107

6/26

32

Metastasis (yes/no)

80/27

107

28/4

32

Brain metastasis (yes/no)

7/100

107

2/30

32

Bone metastasis (yes/no)

9/98

107

6/26

32

Liver metastasis (yes/no)

11/96

107

9/23

32

Adrenal metastasis (yes/no)

10/97

107

4/28

32

Pleural metastasis (yes/no)

7/100

107

5/27

32

Lymph node metastasis (yes/no)

72/35

107

27/5

32

Mediastinal metastasis (yes/no)

3/104

107

1/31

32

Smoking (never/ever)

32/75

107

7/25

32

Smoking amount (BI)

660 (380–970)

73

860 (600–1200)

25

Family cancer history (yes/no)

19/48

67

8/12

20

Exposure to cooking oil fume (never/ever)

32/31

63

7/12

19

Operation (yes/no)

12/95

107

2/30

32

Radiotherapy (yes/no)

52/55

107

9/23

32

Chemotherapy (yes/no)

96/11

107

24/8

32

PLR

115 (89–165)

107

221 (175–324)

32

RBC (10¹²/L)

4.49 (4.17–4.88)

107

4.18 (3.47–4.47)

32

Hb (g/L)

135 (124–146)

107

120 (106–134)

32

MCV (fL)

91.4 (87.8–94.1)

107

92.2 (87.6–93.8)

32

PLT (10⁹/L)

181 (138–228)

107

206 (169–289)

32

WBC (10⁹/L)

6.13 (5.07–7.23)

107

7.34 (6.34–9.75)

32

Neutrophil (10⁹/L)

4.08 (3.00–4.98)

107

5.62 (4.98–7.58)

32

Lymphocyte (10⁹/L)

1.46 (1.22–1.82)

107

0.96 (0.71–1.10)

32

Alb (g/L)

41.2 (38.6–43.6)

104

37.1 (33.0–40.2)

32

LDH (U/L)

193 (175–238)

102

264 (205–360)

31

ALP (U/L)

79 (65–95)

104

82 (59–114)

32

CHO (mmol/L)

4.46 (4.06–4.90)

102

3.87 (3.30–4.47)

31

TG (mmol/L)

1.22 (0.88–1.45)

102

1.06 (0.87–1.46)

31

HDL-C (mmol/L)

1.25 (1.08–1.54)

102

1.09 (0.94–1.34)

31

LDL-C (mmol/L)

2.63 (2.27–3.00)

102

2.23 (1.63–2.72)

31

CR (μmol/L)

76.1 (65.3–87.9)

104

67.6 (55.4–83.7)

32

CEA (ng/ml)

3.71 (1.80–9.13)

85

3.66 (2.04–10.25)

29

CYFRA21-1 (ng/ml)

3.10 (2.27–4.84)

75

4.76 (2.78–7.43)

26

NSE (ng/ml)

38.85 (22.86–97.62)

86

71.29 (37.66–113.23)

26